Table 4.
Observed second-line treatments in the follow-up period
| Frequency of observed treatments in the second LOT following platinum-based therapy based on 79 patients analyzed, N (%) | |
|---|---|
| Observed agents/procedures | |
| Paclitaxel | 16 (20.3%) |
| Carboplatin | 16 (20.3%) |
| Medroxyprogesteronea | 10 (12.7%) |
| Doxorubicina,b | 8 (10.1%) |
| Gemcitabine | 7 (8.9%) |
| Tamoxifen | 6 (7.6%) |
| Megestrola | 6 (7.6%) |
| Trabectedin | 6 (7.6%) |
| 22 other agents/procedures (< 6 patients) | 36 (45.6%) |
| Observed regimen | |
| Medroxyprogesterone (monotherapy) | 7 (8.9%) |
| Carboplatin and paclitaxel | 6 (7.6%) |
| Doxorubicin (monotherapy)b | 6 (7.6%) |
| 42 other combinations (< 6 patients) | 60 (75.9%) |
EC endometrial cancer, LOT line of treatment
aApproved for the EC indication in Germany; bDoxorubicin and liposomal doxorubicin data were captured separately but were not distinguished between in these analyses